Specifications
- Antibody type:Primary
- Antigen name:AVPR1B/AVP Receptor V3
- Clonality:Polyclonal
- Conjugation:Alexa Fluor® 680
- Host:Rabbit
- ImmunoChemistry:Yes
- ImmunoFluorescence:Yes
- Isotype:IgG
- Reactivity:
- Western blot:Yes
- Environmentally Preferable:
- Epitope:23-120/424
- Form:Liquid
- Antigen synonyms:Arginine vasopressin receptor 1B|VPR3|V1BR_HUMAN|Vasopressin V1b receptor|AVPR V3|Vasopressin V3 receptor|AVPR V1b|V1bR|Pituitary vasopressin receptor 3|AVPR3|Arginine vasopressin receptor 3|Avpr1b|Antidiuretic hormone receptor 1b
- Modification:Unmodified
- Storage buffer:Aqueous buffered solution containing 0,01 M TBS (pH 7,4) with 1% BSA, 0,03% Proclin300 and 50% Glycerol
- Molecular weight:47 kDa
- Storage temperature:Store at −20 °C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Concentration:1 µg/µl
- Shipping temperature:4 °C
- Immunogen:KLH conjugated synthetic peptide derived from human AVP Receptor V3
- Tested applications:ICC
- Purification:Purified by Protein A
- Pack type:Vial
- Pk:100 µl
Specifications
About this item
Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterised by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumours (2).
Type: Primary
Antigen: AVPR1B/AVP Receptor V3
Clonality: Polyclonal
Clone:
Conjugation: ALEXA FLUOR® 680
Public Immunogen Range: 23-120/424
Host: Rabbit
Isotype: IgG
Reactivity: